169 nonlinear-systems Postdoctoral positions at University of Oxford in United Kingdom
Sort by
Refine Your Search
-
of Professor Colin Akerman in the Department of Pharmacology. This is a fixed-term post, for six months, funded by the Medical Research Council and is due to start no earlier than January 2026. If successful
-
The University of Oxford is a stimulating work environment, which enjoys an international reputation as a world-class centre of excellence. Our research plays a key role in tackling many global
-
Researcher to join the Translation Biology Research Group led by Mr Alex Gordon-Weeks and Professor Kerry Fisher. The group is focussed on understanding the human tumour microenvironment (TME) and its role in
-
The University of Oxford is a stimulating work environment, which enjoys an international reputation as a world-class centre of excellence. Our research plays a key role in tackling many global
-
181829 – Postdoctoral Research Assistant in Immunology Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences (NDORMS) Grade 7: Salary of £38,674 per annum This is a full
-
A postdoctoral research position is available in the Development of Operando X-ray Photoelectron Spectroscopy within the group of Professor Robert Weatherup in the Department of Materials
-
funded by BBSRC and is fixed-term for 6 months. This project is to develop simple cell (SimCell, non-dividing bacteria cell) based biocatalyst to transform waste from cultured meat process into essential
-
We are seeking a full-time Postdoctoral Research Assistant to join Torr Vision Group at the Department of Engineering Science, central Oxford. The post is funded by EPSRC and is fixed-term
-
THIS IS A RE-ADVERTISEMENT PREVIOUS APPLICANTS NEED NOT APPLY We are seeking a well organised and self-motivated researcher to work on the Faraday Institution funded SOLBAT and/or LiSTAR projects
-
, Surveillance & Exploration). This innovative initiative, established in 2024, is a collaboration between the University of Oxford and GlaxoSmithKline (GSK) aimed at identifying molecular vulnerabilities in